India testing patient India

Diagnostic firms’ valuations get pricey amid health fears

₹1,029 in Q3. For Dr Lal, realization per patient in Q3FY21 stood at ₹824 ( ₹688 in Q3FY20). These firms are also de-risking business models by expanding in new geographies.The firms are expected to report good numbers in Q4, too.

Edelweiss Securities Ltd expects Dr Lal’s top-line to increase 36% y-o-y driven by non-covid testing (up 23%), higher realizations (up 7%) and additional business from covid-19 and allied testing.For Thyrocare, they expect revenue to grow 45% y-o-y led by similar factors.

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News